Skip to main
CLBT

CLBT Stock Forecast & Price Target

CLBT Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cellebrite DI is positioned for success as their AI-powered solutions and global customer base have made them a leader in the digital forensics market. However, competition and potential changes in technology could impact their success, and their reliance on law enforcement and government agencies for revenue presents a potential vulnerability. Cautious expansion and addressing privacy and human rights concerns will be key for their long term growth.

Bears say

Cellebrite DI is facing several fundamental challenges that are causing a negative outlook for the stock. The company operates in an intense market, facing competition from various players of different sizes, which could result in pricing pressure and loss of market share. Additionally, the company's future growth depends heavily on its ability to cross-sell and upsell existing customers, and any decline in its customer relationships could have a significant impact on its revenue and growth prospects. The company also faces the risk of breaches and privacy concerns, which could jeopardize its reputation and result in significant legal and financial consequences. Overall, these challenges pose significant risks to the company's financial performance and could hinder its ability to achieve its growth targets in the long term.

CLBT has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cellebrite DI Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cellebrite DI Ltd (CLBT) Forecast

Analysts have given CLBT a Strong Buy based on their latest research and market trends.

According to 5 analysts, CLBT has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cellebrite DI Ltd (CLBT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.